JP2000506125A5 - - Google Patents

Download PDF

Info

Publication number
JP2000506125A5
JP2000506125A5 JP1997529806A JP52980697A JP2000506125A5 JP 2000506125 A5 JP2000506125 A5 JP 2000506125A5 JP 1997529806 A JP1997529806 A JP 1997529806A JP 52980697 A JP52980697 A JP 52980697A JP 2000506125 A5 JP2000506125 A5 JP 2000506125A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997529806A
Other languages
English (en)
Japanese (ja)
Other versions
JP4184433B2 (ja
JP2000506125A (ja
Filing date
Publication date
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed filed Critical
Priority claimed from PCT/EP1997/000828 external-priority patent/WO1997030721A1/de
Publication of JP2000506125A publication Critical patent/JP2000506125A/ja
Publication of JP2000506125A5 publication Critical patent/JP2000506125A5/ja
Application granted granted Critical
Publication of JP4184433B2 publication Critical patent/JP4184433B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52980697A 1996-02-24 1997-02-21 免疫調節のための医薬組成物 Expired - Fee Related JP4184433B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE19607044.9 1996-02-24
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19638313.7 1996-09-19
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687.4 1996-11-25
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (3)

Publication Number Publication Date
JP2000506125A JP2000506125A (ja) 2000-05-23
JP2000506125A5 true JP2000506125A5 (cg-RX-API-DMAC7.html) 2004-11-25
JP4184433B2 JP4184433B2 (ja) 2008-11-19

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52980697A Expired - Fee Related JP4184433B2 (ja) 1996-02-24 1997-02-21 免疫調節のための医薬組成物

Country Status (34)

Country Link
US (1) US7105162B1 (cg-RX-API-DMAC7.html)
EP (1) EP0881906B2 (cg-RX-API-DMAC7.html)
JP (1) JP4184433B2 (cg-RX-API-DMAC7.html)
KR (1) KR100457647B1 (cg-RX-API-DMAC7.html)
CN (1) CN1177610C (cg-RX-API-DMAC7.html)
AR (1) AR005945A1 (cg-RX-API-DMAC7.html)
AT (1) ATE274350T1 (cg-RX-API-DMAC7.html)
AU (1) AU722264B2 (cg-RX-API-DMAC7.html)
BG (1) BG63682B1 (cg-RX-API-DMAC7.html)
BR (1) BR9707694A (cg-RX-API-DMAC7.html)
CA (1) CA2243559C (cg-RX-API-DMAC7.html)
CO (1) CO4600681A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ295396B6 (cg-RX-API-DMAC7.html)
DE (1) DE59711873D1 (cg-RX-API-DMAC7.html)
DK (1) DK0881906T4 (cg-RX-API-DMAC7.html)
EE (1) EE04481B1 (cg-RX-API-DMAC7.html)
ES (1) ES2225951T5 (cg-RX-API-DMAC7.html)
HR (1) HRP970100B1 (cg-RX-API-DMAC7.html)
HU (1) HU224410B1 (cg-RX-API-DMAC7.html)
ID (1) ID16038A (cg-RX-API-DMAC7.html)
IL (1) IL125361A (cg-RX-API-DMAC7.html)
MY (1) MY119276A (cg-RX-API-DMAC7.html)
NO (1) NO983850L (cg-RX-API-DMAC7.html)
NZ (1) NZ332020A (cg-RX-API-DMAC7.html)
PE (1) PE55398A1 (cg-RX-API-DMAC7.html)
PL (1) PL189413B1 (cg-RX-API-DMAC7.html)
PT (1) PT881906E (cg-RX-API-DMAC7.html)
RO (1) RO119344B1 (cg-RX-API-DMAC7.html)
RS (1) RS50101B (cg-RX-API-DMAC7.html)
SI (1) SI0881906T2 (cg-RX-API-DMAC7.html)
SK (1) SK284582B6 (cg-RX-API-DMAC7.html)
TR (1) TR199801649T2 (cg-RX-API-DMAC7.html)
TW (1) TW585774B (cg-RX-API-DMAC7.html)
WO (1) WO1997030721A1 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP2286834A3 (en) * 1998-02-25 2012-01-25 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response
EP1071411B1 (en) * 1998-04-20 2007-03-14 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
NZ513935A (en) * 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
JP2004519452A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
US7378234B2 (en) 2002-09-13 2008-05-27 Intercell Ag Method for isolating hepatitis C virus peptides
CN1705679B (zh) 2002-10-15 2011-04-06 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
CA2517518A1 (en) 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
EP2182065A3 (en) 2003-03-31 2010-09-15 Intercell AG Staphylococcus epidermidis antigens
EP2311987A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
CN1822856B (zh) 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
WO2005094891A2 (en) 2004-03-12 2005-10-13 Intercell Ag Method for solubilising peptide mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ES2344739T3 (es) 2004-09-24 2010-09-06 Intercell Ag Proteina capsidial vp1 modificada del parvovirus b19.
AU2005298742B2 (en) * 2004-10-29 2010-08-12 Intercell Ag HCV vaccines for chronic HCV patients
ES2396240T3 (es) 2005-04-20 2013-02-20 Mitsuru Akashi Poliaminoácido para usar como adyuvante
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
WO2008135446A2 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
US20100203075A1 (en) 2007-06-18 2010-08-12 Intercell Ag Chlamydia antigens
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US8492331B2 (en) * 2008-03-27 2013-07-23 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates
KR20110091560A (ko) 2008-12-03 2011-08-11 프로테아 벡신 테크놀로지스 엘티디. 글루타밀 tRNA 합성효소(GtS) 단편들
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
CA2772103A1 (en) * 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
ES2882827T3 (es) 2014-10-07 2021-12-02 Cytlimic Inc Péptido inductor de inmunidad derivado de HSP70
MX392028B (es) 2015-05-13 2025-03-04 Agenus Inc Vacunas para el tratamiento y prevención del cáncer.
KR101850417B1 (ko) * 2015-12-16 2018-04-20 주식회사 휴벳바이오 스쿠알렌을 포함하는 양친매성 폴리 아미노산 고분자 기반 백신 면역보조제 조성물
US12065699B2 (en) 2016-03-15 2024-08-20 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
KR20200138418A (ko) * 2016-05-27 2020-12-09 이투빅스 코포레이션 네오에피토프 백신 조성물 및 이의 사용 방법
RU2759728C2 (ru) 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (cg-RX-API-DMAC7.html) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) * 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
WO1991009869A1 (en) 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
PT658113E (pt) 1992-08-31 2005-03-31 Ludwig Inst Cancer Res Nonapeptideo isolado derivado do gene mage-3 e apresentado por hla-a1, e utilizacoes deste
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ3000U1 (cs) * 1993-07-12 1995-02-22 Kufudakis Alekos Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC7.html)
JP2000501771A5 (cg-RX-API-DMAC7.html)
JP2000501599A5 (cg-RX-API-DMAC7.html)
JP2000501018A5 (cg-RX-API-DMAC7.html)
JP2000500076A5 (cg-RX-API-DMAC7.html)
JP2001506384A5 (cg-RX-API-DMAC7.html)
JP2001501842A5 (cg-RX-API-DMAC7.html)
JP2000517347A5 (cg-RX-API-DMAC7.html)
JP2000501324A5 (cg-RX-API-DMAC7.html)
JP2000500055A5 (cg-RX-API-DMAC7.html)
JP2000500026A5 (cg-RX-API-DMAC7.html)
JP2000502472A5 (cg-RX-API-DMAC7.html)
JP2000501825A5 (cg-RX-API-DMAC7.html)
JP2000501338A5 (cg-RX-API-DMAC7.html)
JP2000506125A5 (cg-RX-API-DMAC7.html)
JP2000500874A5 (cg-RX-API-DMAC7.html)
JP2000502485A5 (cg-RX-API-DMAC7.html)
JP2000502425A5 (cg-RX-API-DMAC7.html)
JP2000501774A5 (cg-RX-API-DMAC7.html)
JP2000500912A5 (cg-RX-API-DMAC7.html)
JP2000502570A5 (cg-RX-API-DMAC7.html)
JP2000501876A5 (cg-RX-API-DMAC7.html)
JP2001527601A5 (cg-RX-API-DMAC7.html)
JP2000501744A5 (cg-RX-API-DMAC7.html)
JP2000506890A5 (cg-RX-API-DMAC7.html)